Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

I0782

Sigma-Aldrich

Imazodan

≥99% (HPLC)

Synonym(s):

4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone, Cl 914

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C13H12N4O
CAS Number:
84243-58-3
Molecular Weight:
240.26
MDL number:
MFCD00867109
UNSPSC Code:
41106305
PubChem Substance ID:
24278485

Assay

≥99% (HPLC)

color

yellow, powder

solubility

DMSO: 50 mg/mL, clear, yellow

SMILES string

O=C1CCC(=NN1)c2ccc(cc2)-n3ccnc3

InChI

1S/C13H12N4O/c18-13-6-5-12(15-16-13)10-1-3-11(4-2-10)17-8-7-14-9-17/h1-4,7-9H,5-6H2,(H,16,18)

InChI key

VXMYWVMXSWJFCV-UHFFFAOYSA-N

Gene Information

human ... PDE3A(5139)
rat ... Pde3a(50678)

Biochem/physiol Actions

Selective phoshodiesterase III (PDE3) inhibitor.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
052K3799

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

C P Nielson et al.
The Journal of allergy and clinical immunology, 86(5), 801-808 (1990-11-01)
Modulation of the human polymorphonuclear leukocyte (PMN) respiratory burst by selective cyclic 3',5' adenosine monophosphate (cAMP) phosphodiesterase (PDE) inhibitors was studied with respect to PDE isozyme characteristics. Zaprinast, an inhibitor of a cyclic guanosine monophosphate (cGMP)-specific PDE (PDE I), at
S Terris et al.
The American journal of cardiology, 58(7), 596-600 (1986-09-15)
The hemodynamic effects of CI-914, a phosphodiesterase inhibitor, were studied in 12 patients with left ventricular (LV) dysfunction who were undergoing diagnostic cardiac catheterization. CI-914 was infused intravenously at a rate of 0.8 to 7.0 micrograms/kg/min for 30 to 60
A D Goldberg et al.
The American journal of cardiology, 68(6), 631-636 (1991-09-01)
A 12-week, multicenter, double-blind, randomized, placebo-controlled trial of imazodan, a type III phosphodiesterase inhibitor, was conducted in 147 patients with congestive heart failure to determine clinical efficacy and safety. Patients were randomized to placebo or 2, 5 or 10 mg
R E Weishaar et al.
Journal of cyclic nucleotide and protein phosphorylation research, 10(6), 551-564 (1985-01-01)
In the present study, the inhibitory effects of CI-914, a novel cardiotonic agent, as well as other recently identified positive inotropic agents and reference phosphodiesterase (PDE) inhibitors on the different molecular forms of cardiac PDE were examined, and correlated with
I Sircar et al.
Journal of medicinal chemistry, 30(10), 1724-1728 (1987-10-01)
A series of 2,4-dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-3H-pyrazol-3-ones was synthesized and evaluated for positive inotropic activity. Only compounds with two small alkyl groups at C-4 showed significant activity. The structure-activity relationships for optimal inotropic activity are presented and compared with those of the 4,5-dihydro-3(2H)-pyridazinone
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service